RT Journal Article
T1 Hemodialysis-Associated Immune Dysregulation in SARS-CoV-2-Infected End-Stage Renal Disease Patients
A1 González Cuadrado, Cecilia
A1 Caro Espada, Paula Jara
A1 Chivite Lacaba, Marta
A1 Utrero Rico, Alberto
A1 Lozano Yuste, Claudia
A1 Gutierrez Solis, Elena
A1 Morales Ruiz, Enrique
A1 Sandino Pérez, Justo
A1 Gil Etayo, Francisco Javier
A1 Allende Martínez, Luis Miguel
A1 Laguna Goya, Rocío
A1 Paz Artal, Estela Natividad
AB Patients on hemodialysis show dysregulated immunity, basal hyperinflammation and a marked vulnerability to COVID-19. We evaluated the immune profile in COVID-19 hemodialysis patients and the changes associated with clinical deterioration after the hemodialysis session. Recruited patients included eight hemodialysis subjects with active, PCR-confirmed SARS-CoV-2 infection, five uninfected hemodialysis patients and five healthy controls. In SARS-CoV-2-infected hemodialysis patients TNF-α, IL-6 and IL-8 were particularly increased. Lymphopenia was mostly due to reduction in CD4+ T, B and central memory CD8+ T cells. There was a predominance of classical and intermediate monocytes with reduced HLA-DR expression and enhanced production of pro-inflammatory molecules. Immune parameters were analysed pre- and post-hemodialysis in three patients with COVID-19 symptoms worsening after the hemodialysis session. There was a higher than 2.5-fold increase in GM-CSF, IFN-γ, IL-1β, IL-2, IL-6, IL-17A and IL-21 in serum, and augmentation of monocytes-derived TNF-α, IL-1β and IL-8 and CXCL10 (p < 0.05). In conclusion, COVID-19 in hemodialysis patients associates with alteration of lymphocyte subsets, increasing of pro-inflammatory cytokines and monocyte activation. The observed worsening during the hemodialysis session in some patients was accompanied by augmentation of particular inflammatory cytokines, which might suggest biomarkers and therapeutic targets to prevent or mitigate the hemodialysis-related deterioration during SARS-CoV-2 infection.
PB MDPI
SN 1422-0067
YR 2023
FD 2023-01-15
LK https://hdl.handle.net/20.500.14352/105167
UL https://hdl.handle.net/20.500.14352/105167
LA eng
NO González-Cuadrado, C.; Caro-Espada, P.J.; Chivite-Lacaba, M.; Utrero-Rico, A.; Lozano-Yuste, C.; Gutierrez-Solis, E.; Morales, E.; Sandino-Pérez, J.; Gil-Etayo, F.J.; Allende-Martínez, L.; et al. Hemodialysis-Associated Immune Dysregulation in SARS-CoV-2-Infected End-Stage Renal Disease Patients. Int. J. Mol. Sci. 2023, 24, 1712. https://doi.org/10.3390/ijms24021712
NO Fondos FEDER ; Ayuda Formación del Profesorado FPU19/06393 ; Contrato de Investigaciçon “Rio Hortega” (CM19/00120)
NO European Commission
NO Instituto de Salud Carlos III
NO Ministerio de Ciencia e Innovación (España)
NO Comunidad de Madrid
DS Docta Complutense
RD 25 may 2025